Anticoagulants Reduce Clot Formation on New Heart Valves Post-TAVI Without Increased Bleeding Risk

The ACASA-TAVI trial, presented at ESC Congress 2026 and simultaneously published in JAMA, found that using non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve implantation (TAVI) significantly reduced signs of early blood clots on the new valve compared to standard antiplatelet therapy (aspirin). The study indicated comparable safety between NOACs and aspirin, suggesting NOAC monotherapy could be an effective and safe antithrombotic approach for TAVI patients.